Dominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $44.59, for a total transaction of $780,325.00. Following the transaction, the chief executive officer now owns 195,307 shares in the company, valued at $8,708,739.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dominick Colangelo also recently made the following trade(s):

• On Wednesday, March 13th, Dominick Colangelo sold 17,500 shares of Vericel stock. The shares were sold at an average price of $44.67, for a total transaction of $781,725.00.

Vericel Price Performance

VCEL stock traded down $0.12 on Friday, hitting $43.74. 521,989 shares of the company were exchanged, compared to its average volume of 554,959. Vericel Co. has a twelve month low of $29.24 and a twelve month high of $53.05. The business’s fifty day moving average is $47.64 and its two-hundred day moving average is $40.30. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of -480.33 and a beta of 1.71.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, February 29th. The biotechnology company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.18 by $0.08. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. The firm had revenue of $65.00 million during the quarter, compared to analyst estimates of $64.28 million. During the same quarter in the prior year, the business posted $0.12 earnings per share. Vericel’s revenue for the quarter was up 23.3% compared to the same quarter last year. Equities research analysts expect that Vericel Co. will post 0.09 earnings per share for the current year.

Hedge Funds Weigh In On Vericel

Institutional investors and hedge funds have recently bought and sold shares of the stock. MCF Advisors LLC increased its position in shares of Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares in the last quarter. Gamco Investors INC. ET AL increased its position in shares of Vericel by 1.9% in the second quarter. Gamco Investors INC. ET AL now owns 17,510 shares of the biotechnology company’s stock worth $658,000 after acquiring an additional 325 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Vericel by 8.1% in the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 344 shares in the last quarter. LPL Financial LLC increased its position in shares of Vericel by 6.6% in the second quarter. LPL Financial LLC now owns 8,348 shares of the biotechnology company’s stock worth $314,000 after acquiring an additional 518 shares in the last quarter. Finally, Gotham Asset Management LLC increased its position in shares of Vericel by 3.6% in the third quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company’s stock worth $513,000 after acquiring an additional 538 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have issued reports on VCEL. HC Wainwright upped their price target on shares of Vericel from $46.00 to $53.00 and gave the company a “buy” rating in a report on Friday, March 1st. TheStreet raised shares of Vericel from a “d+” rating to a “c-” rating in a report on Monday, January 29th. Finally, Truist Financial reissued a “buy” rating and issued a $54.00 price objective on shares of Vericel in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.40.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.